Tarsus Pharmaceuticals Inc (TARS)
46.65
+0.15
(+0.32%)
USD |
NASDAQ |
Nov 14, 16:00
46.49
-0.16
(-0.34%)
After-Hours: 20:00
Tarsus Pharmaceuticals Enterprise Value: 1.517B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 1.517B |
| November 12, 2024 | 1.558B |
| November 11, 2024 | 1.615B |
| November 08, 2024 | 1.628B |
| November 07, 2024 | 1.528B |
| November 06, 2024 | 1.528B |
| November 05, 2024 | 1.485B |
| November 04, 2024 | 1.506B |
| November 01, 2024 | 1.547B |
| October 31, 2024 | 1.440B |
| October 30, 2024 | 1.450B |
| October 29, 2024 | 1.417B |
| October 28, 2024 | 1.257B |
| October 25, 2024 | 1.247B |
| October 24, 2024 | 1.227B |
| October 23, 2024 | 1.232B |
| October 22, 2024 | 1.194B |
| October 21, 2024 | 1.135B |
| October 18, 2024 | 1.141B |
| October 17, 2024 | 1.158B |
| October 16, 2024 | 1.178B |
| October 15, 2024 | 1.166B |
| October 14, 2024 | 1.136B |
| October 11, 2024 | 1.106B |
| October 10, 2024 | 1.098B |
| Date | Value |
|---|---|
| October 09, 2024 | 1.069B |
| October 08, 2024 | 1.041B |
| October 07, 2024 | 1.011B |
| October 04, 2024 | 1.037B |
| October 03, 2024 | 975.60M |
| October 02, 2024 | 993.86M |
| October 01, 2024 | 976.36M |
| September 30, 2024 | 999.19M |
| September 27, 2024 | 984.73M |
| September 26, 2024 | 1.009B |
| September 25, 2024 | 979.79M |
| September 24, 2024 | 1.005B |
| September 23, 2024 | 1.010B |
| September 20, 2024 | 1.061B |
| September 19, 2024 | 1.064B |
| September 18, 2024 | 986.26M |
| September 17, 2024 | 929.19M |
| September 16, 2024 | 960.77M |
| September 13, 2024 | 1.013B |
| September 12, 2024 | 953.92M |
| September 11, 2024 | 957.72M |
| September 10, 2024 | 944.03M |
| September 09, 2024 | 936.80M |
| September 06, 2024 | 911.69M |
| September 05, 2024 | 786.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
111.68M
Minimum
May 04 2022
1.628B
Maximum
Nov 08 2024
457.51M
Average
350.17M
Median
Jul 19 2021
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.241B |
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.29M |
| Revenue (Quarterly) | 40.81M |
| Total Expenses (Quarterly) | 74.12M |
| EPS Diluted (Quarterly) | -0.88 |
| Gross Profit Margin (Quarterly) | 92.64% |
| Profit Margin (Quarterly) | -81.57% |
| Earnings Yield | -9.60% |
| Normalized Earnings Yield | -9.472 |